PSTV Plus Therapeutics, Inc.
Healthcare$6.59-4.35%ClosedMarket Cap: $15.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
3.66
P/S
3.08
EV/EBITDA
-1.62
DCF Value
$-0.88
FCF Yield
-136.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.8%
Operating Margin
-364.4%
Net Margin
-230.2%
ROE
-198.5%
ROA
-59.9%
ROIC
-148.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.0M | 89.4% | $-7.1M | $-6.9M | $— | — |
| Q4 null | $1.4M | 93.3% | $-5.7M | $-5.7M | $— | — |
| FY null | $5.2M | 91.5% | $-15.3M | $-22.4M | $— | — |
| Q3 null | $1.4M | 93.8% | $-4.5M | $-4.4M | $— | — |
| Q2 null | $1.4M | 93.8% | $-1.5M | $5.2M | $— | — |
| Q1 null | $1.1M | 82.9% | $-3.5M | $-17.4M | $— | — |
| Q4 null | $1.4M | 83.6% | $-3.9M | $-3.9M | $— | — |
| FY null | $5.8M | 85.4% | $-14.7M | $-13.0M | $— | — |
| Q3 null | $1.5M | 84.1% | $-3.8M | $-2.9M | $— | — |
| Q2 null | $1.3M | 84.2% | $-3.7M | $-2.9M | $— | — |
| Q1 null | $1.7M | 88.9% | $-3.3M | $-3.3M | $— | — |
| Q4 2023 | $1.3M | 86.1% | $-3.9M | $-3.8M | $-21,250.00 | — |